300 related articles for article (PubMed ID: 38183131)
21. Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy.
Aerts A; Impens NR; Gijs M; D'Huyvetter M; Vanmarcke H; Ponsard B; Lahoutte T; Luxen A; Baatout S
Curr Pharm Des; 2014; 20(32):5218-44. PubMed ID: 24606796
[TBL] [Abstract][Full Text] [Related]
22. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
23. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
24. Theranostics: The Role of Quantitative Nuclear Medicine Imaging.
Könik A; O'Donoghue JA; Wahl RL; Graham MM; Van den Abbeele AD
Semin Radiat Oncol; 2021 Jan; 31(1):28-36. PubMed ID: 33246633
[TBL] [Abstract][Full Text] [Related]
25. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice.
Sheikhbahaei S; Sadaghiani MS; Rowe SP; Solnes LB
AJR Am J Roentgenol; 2021 Aug; 217(2):495-506. PubMed ID: 34076455
[No Abstract] [Full Text] [Related]
26. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
27. Radiopharmaceuticals used for diagnosis and therapy of NETs.
Papachristou M
Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
[TBL] [Abstract][Full Text] [Related]
28. Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach.
Filippi L; Urso L; Bianconi F; Palumbo B; Marzola MC; Evangelista L; Schillaci O
Expert Rev Mol Diagn; 2023 Mar; 23(3):243-255. PubMed ID: 36927210
[TBL] [Abstract][Full Text] [Related]
29. Radiopharmaceutical Delivery for Theranostics: Pharmacokinetics and Pharmacodynamics.
Sunderland JJ; Ponto LB; Capala J
Semin Radiat Oncol; 2021 Jan; 31(1):12-19. PubMed ID: 33246631
[TBL] [Abstract][Full Text] [Related]
30. GRPr Theranostics: Current Status of Imaging and Therapy using GRPr Targeting Radiopharmaceuticals.
Kurth J; Potratz M; Heuschkel M; Krause BJ; Schwarzenböck SM
Nuklearmedizin; 2022 Jun; 61(3):247-261. PubMed ID: 35668669
[TBL] [Abstract][Full Text] [Related]
31. Aptamer-Based Smart Targeting and Spatial Trigger-Response Drug-Delivery Systems for Anticancer Therapy.
Park D; Lee SJ; Park JW
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255292
[TBL] [Abstract][Full Text] [Related]
32. Radionuclide-based theranostics - a promising strategy for lung cancer.
Zhu T; Hsu JC; Guo J; Chen W; Cai W; Wang K
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2353-2374. PubMed ID: 36929181
[TBL] [Abstract][Full Text] [Related]
33. Antibody-based Radiopharmaceuticals as Theranostic Agents: An Overview.
Sharma R; Suman SK; Mukherjee A
Curr Med Chem; 2022; 29(38):5979-6005. PubMed ID: 35674298
[TBL] [Abstract][Full Text] [Related]
34. Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation.
Sun J; Huangfu Z; Yang J; Wang G; Hu K; Gao M; Zhong Z
Adv Drug Deliv Rev; 2022 Nov; 190():114538. PubMed ID: 36162696
[TBL] [Abstract][Full Text] [Related]
35. Radiotheranostics in oncology: Making precision medicine possible.
Aboagye EO; Barwick TD; Haberkorn U
CA Cancer J Clin; 2023; 73(3):255-274. PubMed ID: 36622841
[TBL] [Abstract][Full Text] [Related]
36. SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: a comprehensive multidisciplinary team approach.
Werner RA; Bluemel C; Lassmann M; Kudlich T; Higuchi T; Lopci E; Allen-Auerbach M; Colletti PM; Rubello D; Zatelli MC; Herrmann K
Clin Nucl Med; 2015 May; 40(5):e271-7. PubMed ID: 25642915
[TBL] [Abstract][Full Text] [Related]
37. From Bench to Bedside-The Bad Berka Experience With First-in-Human Studies.
Zhang J; Singh A; Kulkarni HR; Schuchardt C; Müller D; Wester HJ; Maina T; Rösch F; van der Meulen NP; Müller C; Mäcke H; Baum RP
Semin Nucl Med; 2019 Sep; 49(5):422-437. PubMed ID: 31470935
[TBL] [Abstract][Full Text] [Related]
38. Molecular imaging Theranostics of Neuroendocrine Tumors.
Fortunati E; Bonazzi N; Zanoni L; Fanti S; Ambrosini V
Semin Nucl Med; 2023 Jul; 53(4):539-554. PubMed ID: 36623974
[TBL] [Abstract][Full Text] [Related]
39. The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker.
Holik HA; Ibrahim FM; Elaine AA; Putra BD; Achmad A; Kartamihardja AHS
Molecules; 2022 May; 27(10):. PubMed ID: 35630536
[TBL] [Abstract][Full Text] [Related]
40. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
